Product Images Avonex Pen
View Photos of Packaging, Labels & Appearance
- avo08 0020 01
- avo08 0020 02
- avo08 0020 03
- avo08 0020 04
- avo08 0020 05
- avo08 0020 06
- avo08 0020 07
- avo08 0020 08
- avo08 0020 09
- avo08 0020 10
- avo08 0020 11
- avo08 0020 12
- avo08 0020 13
- avo08 0020 14
- avo08 0020 15
- avo08 0020 16
- avo08 0020 17
- avo08 0020 18
- avo08 0020 19
- avo08 0020 20
- avo08 0020 21
- avo08 0020 22
- avo08 0020 23
- avo08 0020 24
- avo08 0020 25
- avo08 0020 26
- avo08 0020 27
- avo08 0020 28
- avo08 0020 29
- avo08 0020 30
- avo08 0020 31
- avo08 0020 32
- avo08 0020 33
- avo08 0020 34
- avo08 0020 35
- avo08 0020 36
- avo08 0020 37
- avo08 0020 38
- avo08 0020 39
- avo08 0020 40
- avo08 0020 41
- avo08 0020 42
- avo08 0020 43
- avo08 0020 44
- avo08 0020 45
- avo08 0020 46
- avo08 0020 47
- avo08 0020 48
- avo08 0020 49
- avo08 0020 50
- avo08 0020 51
- avo08 0020 52
- avo08 0020 53
- avo08 0020 54
- avo08 0020 55
- avo08 0020 56
- avo08 0020 57
- avo08 0020 58
- avo08 0020 59
- avo08 0020 60
- avo08 0020 61
- avo08 0020 62
- avo08 0020 63
- avo08 0020 64
- avo08 0020 65
- avo08 0020 66
Product Label Images
The following 66 images provide visual information about the product associated with Avonex Pen NDC 59627-003 by Biogen Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
avo08 0020 01
This appears to be a graph showing the time to onset of sustained disability progression in patients with MS in Study 1. The graph compares the results of patients treated with AVONEX versus a placebo, with the percentage of patients progressing indicated on the y-axis and time in weeks on the x-axis. The text notes that there was a statistically significant difference between the two treatment groups (P=0.02).*
avo08 0020 02
The text describes a figure (Figure 2) showing the percentage of patients with confirmed change in EDSS (Expanded Disability Status Scale) from study entry to the end of Study 1, represented by two groups: B AVONEX (sample size of 150) and Placebo (sample size of 136). The figure shows a statistical significance (P=0.006) between the two groups. The x-axis represents the confirmed change from baseline EDSS and the y-axis shows the percentage of patients. The figure is divided into "Better" and "Worse" outcomes. No further information is available in the text.*
avo08 0020 03
This text describes a figure (Figure 3) that shows the time it takes for a second exacerbation to occur in two different groups (AVONEX and placebo) over a period of 36 months. The graph displays the number of subjects at risk in each group at various time points. Additionally, the data indicates that there is significant difference between AVONEX and placebo groups in terms of their rate ratio, with a p-value of 0.002 and rate ratio of 0.56.*
avo08 0020 04
The text describes different components of a medical device named Avonex Pen. The components mentioned are a blue activation button with a tamper-evident cap, a Body Injector Shield with a grooved area, a Needle Cover, and a Foil.*
avo08 0020 05
avo08 0020 06
avo08 0020 07
This is a glass syringe tip, which is a component typically used in laboratory and medical settings for dispensing and transferring small volumes of liquid substances. It is made of glass, which is a material known for its transparency, chemical resistance, and inertness, making it ideal for handling various types of fluids. The syringe tip is designed to fit and attach to the end of a syringe barrel, creating a precise and secure connection that can be used for accurate measuring and dosing.*
avo08 0020 08
avo08 0020 09
avo08 0020 10
avo08 0020 11
avo08 0020 12
avo08 0020 13
avo08 0020 14
This is a short text with only one word and one phrase. The word is "Safety" and it is unclear what it refers to as there is no further context. The second part of the text is "Lock (visible)", which seems to indicate that there is a lock that is visible, possibly for safety purposes. However, without additional information, it is difficult to determine the exact meaning and purpose of this text.*
avo08 0020 15
This text is not sufficient to generate a useful description.*
avo08 0020 16
avo08 0020 17
avo08 0020 18
avo08 0020 19
avo08 0020 20
avo08 0020 21
avo08 0020 22
avo08 0020 23
avo08 0020 24
avo08 0020 25
avo08 0020 26
avo08 0020 27
avo08 0020 28
It appears that the text contains only fragmented words and characters. Hence, it is not readable and the description cannot be generated.*
avo08 0020 29
avo08 0020 30
avo08 0020 31
avo08 0020 32
This text refers to a medical instrument called "syringe tip". It is a small, pointed end of a syringe that enables medical practitioners to administer medication or draw blood.*
avo08 0020 33
avo08 0020 34
avo08 0020 35
avo08 0020 36
avo08 0020 37
avo08 0020 38
This text refers to a plunger, a tool used for unclogging toilets or drains by creating suction.*
avo08 0020 39
avo08 0020 40
avo08 0020 41
avo08 0020 42
avo08 0020 43
avo08 0020 44
avo08 0020 45
avo08 0020 46
avo08 0020 47
avo08 0020 48
avo08 0020 49
avo08 0020 50
avo08 0020 51
avo08 0020 52
avo08 0020 53
avo08 0020 54
avo08 0020 55
avo08 0020 56
avo08 0020 57
avo08 0020 58
avo08 0020 59
avo08 0020 60
avo08 0020 61
avo08 0020 62
Avonex Pen is a weekly dosage medication that contains interferon beta-1a which is administered via intramuscular injection. It is stored in the original carton at a temperature between 2°C to 8°C to protect it from light and should not be exposed to high temperatures or frozen. The injection is provided in a pre-filled autoinjector that may be stored at room temperature for a maximum of 7 days. The product contains natural rubber latex, which may cause allergies. The enclosed medication guide should be dispensed with each patient's prescription, and the prescribing information should be referred to for proper dosage information.*
avo08 0020 63
Avonex Injection is a weekly dose pack treatment containing Interferon beta-1a. It is available in single-dose prefilled syringes for intramuscular injection, and can be stored at room temperature up to 25°C (77°F) for 7 days. Each syringe delivers 30 micrograms of interferon beta-1a and is preserved using natural rubber. The medication guide should be dispensed to each patient.*
avo08 0020 64
This is a product description for the Avonex Pen, which is a medication used for treatment of multiple sclerosis. The product contains four pre-filled autoinjectors of interferon beta-1a, which need to be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Each autoinjector includes a needle and plunger and is equipped with an adhesive bandage and alcohol wipe. Patients should be dispensed the enclosed medication guide. The NDC number for this product is 59627-333.04*
avo08 0020 65
This text is a product description for Avonex, an interferon beta-1a injection. Avonex comes in a 30 mcg/0.5 mL single-dose prefilled syringe, is intended for intramuscular injection, and is administered once a week. Each Avonex administration dose pack contains one prefilled syringe and one injection needle, and there are four Avonex administration dose packs per container. The product does not contain preservatives or rubber latex. It should be stored refrigerated between 2°C and 8°C and protected from light. The medication guide should be dispensed to each patient. The manufacturer is Biogen Inc. The dosage instructions are included in the prescribing information.*
avo08 0020 66
Avonex® is a drug that contains interferon beta-1a and is administered through intramuscular injection. It comes in a single-dose prefilled syringe with a 1 1/4" needle and must be stored in a refrigerator at a temperature of 2°C to 8°C (36°F to 46°F) to be protected from light. The package insert contains information on dosage and administration. The product contains natural rubber latex and can cause allergic reactions. The medication guide enclosed with the product must be given to the patient. The manufacturer of Avonex is Biogen Inc., located in Cambridge, MA. The product is only available with a prescription and has a National Drug Code of 59627-002-07.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
